Evidence map›Paper›PMID 33269016›Full record

ArticleJournal of medical biochemistry2020

Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.

Agnieszka Ćwiklińska, Agnieszka Mickiewicz, Robert Kowalski, Barbara Kortas-Stempak, Agnieszka Kuchta, Krzysztof Mucha, Michał Makowiecki, Anna Gliwińska, Krzysztof Lewandowski, Leszek Pączek and 3 more

Abstract read
In one paragraph

Article in Journal of medical biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. [A case of acetaminophen-induced cholestatic liver injury accompanying severe hypercholesterolemia in children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  2. Lipidome remodeling in primary biliary cholangitis.Lipids in health and disease · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Agnieszka ĆwiklińskaMedical University of Gdansk, Department of Clinical Chemistry, Gdansk, Poland.
Agnieszka MickiewiczMedical University of Gdansk, 1st Department of Cardiology, Gdansk, Poland.
Robert KowalskiMedical University of Gdansk, Hospital Pharmacy of the University Clinical Centre, Gdansk, Poland.
Barbara Kortas-StempakMedical University of Gdansk, Department of Clinical Chemistry, Gdansk, Poland.
Agnieszka KuchtaMedical University of Gdansk, Department of Clinical Chemistry, Gdansk, Poland.
Krzysztof MuchaMedical University of Warsaw, Transplantation Institute, Department of Immunology, Transplantology and Internal Medicine, Warsaw, Poland.
Michał MakowieckiMedical University of Gdansk, Central Laboratory of the University Clinical Centre, Gdansk, Poland.
Anna GliwińskaMedical University of Gdansk, Department of Clinical Chemistry, Gdansk, Poland.
Krzysztof LewandowskiMedical University of Gdansk, Department of Laboratory Medicine, Gdansk, Poland.
Leszek PączekMedical University of Warsaw, Transplantation Institute, Department of Immunology, Transplantology and Internal Medicine, Warsaw, Poland.
Marcin FijałkowskiMedical University of Gdansk, 1st Department of Cardiology, Gdansk, Poland.
Marcin GruchałaMedical University of Gdansk, 1st Department of Cardiology, Gdansk, Poland.
Maciej JankowskiMedical University of Gdansk, Department of Clinical Chemistry, Gdansk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipoprotein X (LpX) is an abnormal lipoprotein fraction, which can be detected in patients with severe hypercholesterolaemia and cholestatic liver disease. LpX is composed largely of phospholipid and free cholesterol, with small amounts of triglyceride, cholesteryl ester and protein. There are no widely available methods for direct measurement of LpX in routine laboratory practice. We present the heterogeneity of clinical and laboratory manifestations of the presence of LpX, a phenomenon which hinders LpX detection.

methodsThe study was conducted on a 26-year-old female after liver transplantation (LTx) with severely elevated total cholesterol (TC) of 38 mmol/L and increased cholestatic liver enzymes. TC, free cholesterol (FC), cholesteryl esters (CE), triglycerides, phospholipids, HDL-C, LDL-C, and apolipoproteins AI and B were measured. TC/apoB and FC:CE ratios were calculated. Lipoprotein electrophoresis was performed using a commercially available kit and laboratory-prepared agarose gel.

resultsCommercially available electrophoresis failed to demonstrate the presence of LpX. Laboratory-prepared gel clearly revealed the presence of lipoproteins with γ mobility, characteristic of LpX. The TC/apoB ratio was elevated and the CE level was reduced, confirming the presence of LpX. Regular lipoprotein apheresis was applied as the method of choice in LpX disease and a bridge to reLTx due to chronic liver insufficiency.

conclusionsThe detection of LpX is crucial as it may influence the method of treatment. As routinely available biochemical laboratory tests do not always indicate the presence of LpX, in severe hypercholesterolaemia with cholestasis, any discrepancy between electrophoresis and biochemical tests should raise suspicions of LpX disease.

Indexed as

cholestasiselectrophoresishepatobiliary disorderslipoprotein Xsevere hypercholesterolaemia

Identifiers

PMID33269016
PMCPMC7682847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.